文献速递脑血管病

肾功能对真实世界房颤患者艾多沙班疗效的影响

Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
PubMed 文献 · Stroke · 2018-01-01

基于韩国国民健康保险数据,纳入9537例艾多沙班治疗的房颤患者,比较高剂量(60mg/日)和低剂量(30mg/日)艾多沙班与倾向评分匹配的华法林组的有效性和安全性。中位随访5.0个月,两种剂量艾多沙班均较华法林降低缺血性卒中或体循环栓塞、大出血和死亡风险;但在肌酐清除率>95 mL/min患者中,低剂量艾多沙班预防卒中或体循环栓塞的效果低于华法林。

要点

  • 高剂量艾多沙班较华法林降低卒中或体循环栓塞风险(aHR 0.44)、大出血风险(aHR 0.40)和死亡风险(aHR 0.34)。
  • 低剂量艾多沙班较华法林降低卒中或体循环栓塞风险(aHR 0.57)、大出血风险(aHR 0.61)和死亡风险(aHR 0.55)。
  • 肌酐清除率>95 mL/min患者中,低剂量艾多沙班预防卒中或体循环栓塞效果低于华法林(交互作用P=0.023)。

核心结论

  • 真实世界实践中,高剂量和低剂量艾多沙班均较华法林降低卒中或体循环栓塞、大出血和死亡风险。
  • 肌酐清除率>95 mL/min患者中,低剂量艾多沙班预防卒中或体循环栓塞效果低于华法林。

研究设计与样本

  • 基于韩国国民健康保险服务2016年1月至12月数据,识别9537例艾多沙班治疗的房颤患者。
  • 高剂量艾多沙班组(60mg/日,n=2840)与倾向评分匹配华法林组(n=2840)比较。
  • 低剂量艾多沙班组(30mg/日,n=3016)与倾向评分匹配华法林组(n=3016)比较。

主要发现

  • 中位随访5.0个月(四分位距2-7个月);高剂量组平均年龄68岁、男性63%,低剂量组平均年龄73岁、男性52%。
  • 高剂量艾多沙班较华法林降低卒中或体循环栓塞风险(aHR 0.44,95%CI 0.31-0.64)、大出血风险(aHR 0.40,95%CI 0.26-0.61)和死亡风险(aHR 0.34,95%CI 0.22-0.53)。
  • 低剂量艾多沙班较华法林降低卒中或体循环栓塞风险(aHR 0.57,95%CI 0.42-0.78)、大出血风险(aHR 0.61,95%CI 0.43-0.85)和死亡风险(aHR 0.55,95%CI 0.41-0.73)。
  • 肌酐清除率>95 mL/min患者中,低剂量艾多沙班组卒中或体循环栓塞发生率高于华法林组,高剂量组与华法林组相当。
  • 较高肌酐清除率水平下低剂量艾多沙班预防卒中或体循环栓塞效果低于华法林(交互作用P=0.023)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial fibrillation. Concerns have been raised about an excess of stroke among patients with creatinine clearance (CrCl) >95 mg/mL treated with edoxaban. We assessed the real-world effectiveness and safety of edoxaban in atrial fibrillation patients in relation to CrCl. Methods- In the Korean National Health Insurance Service data during the period from January to December 2016, we identified 9537 edoxaban-treated patients. Effectiveness and safety outcomes were compared between high-dose edoxaban regimen (HDER, 60 mg daily, n=2840) and a propensity score-matched warfarin group (n=2840) and between low-dose edoxaban regimen (LDER, 30 mg daily, n=3016) and matched warfarin group (n=3016). Results- The median follow-up period was 5.0 months (interquartile range, 2-7 months). The mean age was 68 years, and 63% were men in HDER group, and the mean age was 73 years, and 52% were men in LDER group. Compared with warfarin, both HDER and LDER significantly decreased the risk for ischemic stroke or systemic embolism (S/SE; HDER: adjusted hazard ratio [aHR], 0.44; 95% CI, 0.31-0.64; LDER: aHR, 0.57; 95% CI, 0.42-0.78), major bleeding (HDER: aHR, 0.40; 95% CI, 0.26-0.61; LDER: aHR, 0.61; 95% CI, 0.43-0.85), and mortality (HDER: aHR, 0.34; 95% CI, 0.22-0.53; LDER: aHR, 0.55; 95% CI, 0.41-0.73). In patients with CrCl >95 mL/min, the incidence of S/SE was higher with LDER than warfarin and comparable between HDER and warfarin group. There was lower effectiveness for the prevention of S/SE with LDER compared with warfarin at higher CrCl levels ( P for interaction=0.023). Conclusions- In real-world practice, both doses of edoxaban were associated with reduced risks for S/SE, major bleeding, and mortality compared with warfarin. LDER had lower effectiveness for the prevention of S/SE compared with warfarin at higher levels of CrCl (>95 mL/min).

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yu HT, Yang PS, Kim TH, et al. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. Stroke. 2018. PMID: 30355093. doi:10.1161/STROKEAHA.118.021387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。